Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.
Clinical trials sponsored by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., explained in plain language.
A Chinese medical device company specializing in endovascular and vascular interventional products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Minimally invasive stent graft for aortic aneurysm under Real-World scrutiny
Disease control Recruiting nowThis study follows about 200 people with abdominal aortic aneurysms who receive the Minos stent graft, a device placed through small groin incisions to reinforce the weakened aorta. Researchers track how well the device works and its safety over up to 5 years in everyday hospital…
Sponsor: Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New stent grafts tested for aortic repair in european registry
Disease control Recruiting nowThis registry is tracking how well two stent grafts, Castor and Cratos, work for treating aortic conditions like dissections and aneurysms. About 100 patients across European hospitals will be followed for up to 5 years. The goal is to see if these devices are safe and effective …
Sponsor: Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC